Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
Jazz Pharmaceuticals has announced its participation in the upcoming BofA Securities 2025 Healthcare Conference. The company's management will engage in a fireside chat scheduled for May 14, 2025, at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.
The event will be accessible via audio webcast through the Investors section of Jazz Pharmaceuticals' website, with a 30-day replay available. Jazz Pharmaceuticals, listed on Nasdaq as JAZZ, is a global biopharma company focused on developing life-changing medicines for patients with serious diseases, particularly in areas with limited treatment options.
The company maintains a diverse portfolio including:
- Leading therapies for sleep disorders and epilepsy
- Growing portfolio of cancer treatments
- Innovative pipeline in oncology and neuroscience
Headquartered in Dublin, Ireland, Jazz operates research and development laboratories and manufacturing facilities across multiple countries.
Jazz Pharmaceuticals ha annunciato la sua partecipazione alla prossima BofA Securities 2025 Healthcare Conference. Il management dell'azienda parteciperà a una discussione informale prevista per il 14 maggio 2025, alle ore 10:00 PT / 13:00 ET / 18:00 IST.
L'evento sarà accessibile tramite webcast audio nella sezione Investitori del sito web di Jazz Pharmaceuticals, con una replica disponibile per 30 giorni. Jazz Pharmaceuticals, quotata al Nasdaq con il simbolo JAZZ, è un'azienda biopharma globale focalizzata sullo sviluppo di farmaci innovativi per pazienti con malattie gravi, soprattutto in aree con opzioni terapeutiche limitate.
L'azienda dispone di un portafoglio diversificato che include:
- Terapie di punta per disturbi del sonno ed epilessia
- Un portafoglio in crescita di trattamenti oncologici
- Un pipeline innovativa in oncologia e neuroscienze
Con sede a Dublino, Irlanda, Jazz gestisce laboratori di ricerca e sviluppo e impianti di produzione in diversi paesi.
Jazz Pharmaceuticals ha anunciado su participación en la próxima Conferencia de Salud BofA Securities 2025. La dirección de la empresa participará en una charla informal programada para el 14 de mayo de 2025, a las 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.
El evento estará disponible mediante webcast de audio en la sección de Inversores del sitio web de Jazz Pharmaceuticals, con una repetición accesible durante 30 días. Jazz Pharmaceuticals, cotizada en Nasdaq con el símbolo JAZZ, es una compañía biofarmacéutica global enfocada en desarrollar medicamentos que cambian la vida para pacientes con enfermedades graves, especialmente en áreas con opciones de tratamiento limitadas.
La empresa mantiene un portafolio diverso que incluye:
- Terapias líderes para trastornos del sueño y epilepsia
- Un portafolio en crecimiento de tratamientos contra el cáncer
- Una innovadora cartera de proyectos en oncología y neurociencia
Con sede en Dublín, Irlanda, Jazz opera laboratorios de investigación y desarrollo y plantas de fabricación en varios países.
Jazz Pharmaceuticals는 다가오는 BofA Securities 2025 Healthcare Conference에 참여한다고 발표했습니다. 회사 경영진은 2025년 5월 14일 오전 10시 PT / 오후 1시 ET / 오후 6시 IST에 예정된 대화 시간에 참여할 예정입니다.
이 행사는 Jazz Pharmaceuticals 웹사이트의 투자자 섹션을 통해 오디오 웹캐스트로 제공되며, 30일간 다시보기 서비스가 제공됩니다. Nasdaq에 JAZZ로 상장된 Jazz Pharmaceuticals는 심각한 질병을 가진 환자들을 위한 혁신적인 의약품 개발에 주력하는 글로벌 바이오제약 회사입니다. 특히 치료 옵션이 제한된 분야에 집중하고 있습니다.
회사는 다음과 같은 다양한 포트폴리오를 보유하고 있습니다:
- 수면 장애 및 간질 치료를 위한 선도적인 치료제
- 성장 중인 암 치료제 포트폴리오
- 종양학 및 신경과학 분야의 혁신적인 파이프라인
본사는 아일랜드 더블린에 위치하며, 여러 국가에 연구개발 실험실과 제조 시설을 운영하고 있습니다.
Jazz Pharmaceuticals a annoncé sa participation à la prochaine Conférence Healthcare BofA Securities 2025. La direction de l'entreprise prendra part à une discussion informelle prévue le 14 mai 2025 à 10h00 PT / 13h00 ET / 18h00 IST.
L'événement sera accessible via un webcast audio dans la section Investisseurs du site web de Jazz Pharmaceuticals, avec une rediffusion disponible pendant 30 jours. Jazz Pharmaceuticals, cotée au Nasdaq sous le symbole JAZZ, est une société biopharmaceutique mondiale spécialisée dans le développement de médicaments révolutionnaires pour les patients atteints de maladies graves, en particulier dans des domaines où les options de traitement sont limitées.
L'entreprise dispose d'un portefeuille diversifié comprenant :
- Des thérapies de pointe pour les troubles du sommeil et l'épilepsie
- Un portefeuille croissant de traitements contre le cancer
- Un pipeline innovant en oncologie et neurosciences
Basée à Dublin, en Irlande, Jazz exploite des laboratoires de recherche et développement ainsi que des sites de production dans plusieurs pays.
Jazz Pharmaceuticals hat seine Teilnahme an der bevorstehenden BofA Securities 2025 Healthcare Conference angekündigt. Das Management des Unternehmens wird an einem Fireside-Chat am 14. Mai 2025 um 10:00 Uhr PT / 13:00 Uhr ET / 18:00 Uhr IST teilnehmen.
Die Veranstaltung ist über einen Audio-Webcast im Investor-Bereich der Website von Jazz Pharmaceuticals zugänglich, mit einer 30-tägigen Wiederholungsmöglichkeit. Jazz Pharmaceuticals, an der Nasdaq unter dem Kürzel JAZZ gelistet, ist ein globales Biopharma-Unternehmen, das sich auf die Entwicklung lebensverändernder Medikamente für Patienten mit schweren Erkrankungen konzentriert, insbesondere in Bereichen mit begrenzten Behandlungsmöglichkeiten.
Das Unternehmen verfügt über ein vielfältiges Portfolio, das Folgendes umfasst:
- Führende Therapien für Schlafstörungen und Epilepsie
- Ein wachsendes Portfolio an Krebsbehandlungen
- Innovative Pipeline in den Bereichen Onkologie und Neurowissenschaften
Der Hauptsitz befindet sich in Dublin, Irland. Jazz betreibt Forschungs- und Entwicklungslabore sowie Produktionsstätten in mehreren Ländern.
- Diversified portfolio including leading therapies in sleep disorders and epilepsy
- Growing portfolio of cancer treatments
- Global presence with R&D labs and manufacturing facilities in multiple countries
- Active pipeline in oncology and neuroscience development
- None.
An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in
Contacts:
Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2025-healthcare-conference-302442981.html
SOURCE Jazz Pharmaceuticals plc
FAQ
When is Jazz Pharmaceuticals (JAZZ) presenting at the BofA Securities Healthcare Conference 2025?
How can investors watch Jazz Pharmaceuticals' (JAZZ) BofA Securities conference presentation?
What therapeutic areas does Jazz Pharmaceuticals (JAZZ) focus on in 2025?
Where is Jazz Pharmaceuticals (JAZZ) headquartered and what markets do they serve?
How can investors contact Jazz Pharmaceuticals (JAZZ) investor relations?
